Which has better valuation and earnings, PSNL or SHC?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.67M 21.10 -$81.27M -$1.09 N/A Sotera Health $1.16B 4.63 $77.94M $0.57 33.14

Is PSNL or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Sotera Health 13.44% 40.12% 7.55%

Does the media refer more to PSNL or SHC?

In the previous week, Sotera Health had 12 more articles in the media than Personalis. MarketBeat recorded 15 mentions for Sotera Health and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Sotera Health's score of 0.57 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sotera Health 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PSNL or ADPT?

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Personalis. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Adaptive Biotechnologies' score of 0.94 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or PSNL?

In the previous week, Alamar Biosciences had 14 more articles in the media than Personalis. MarketBeat recorded 17 mentions for Alamar Biosciences and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Alamar Biosciences' score of 0.57 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, FTRE or PSNL?

Personalis has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.68B 0.62 -$986.20M -$0.91 N/A Personalis $69.67M 21.10 -$81.27M -$1.09 N/A

Is FTRE or PSNL more profitable?

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Personalis -153.84% -46.47% -35.30%

Does the media prefer FTRE or PSNL?

In the previous week, Fortrea had 8 more articles in the media than Personalis. MarketBeat recorded 11 mentions for Fortrea and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Fortrea's score of 0.96 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PSNL or BLFS?

In the previous week, BioLife Solutions had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for BioLife Solutions and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat BioLife Solutions' score of 0.52 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Personalis (PSNL) Competitors

$14.04 -0.38 (-2.64%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.30 +0.26 (+1.82%)

As of 08/14/2026 07:50 PM Eastern

Compare

PSNL vs. SHC, ADPT, ALMR, FTRE, and BLFS

Should you buy Personalis stock or one of its competitors? Personalis's main competitors and comparable companies include Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), Fortrea (FTRE), and BioLife Solutions (BLFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Personalis compare to Sotera Health?

Personalis (NASDAQ:PSNL) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	21.10	-$81.27M	-$1.09	N/A
Sotera Health	$1.16B	4.63	$77.94M	$0.57	33.14

Personalis has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Sotera Health had 12 more articles in the media than Personalis. MarketBeat recorded 15 mentions for Sotera Health and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Sotera Health's score of 0.57 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Sotera Health	13.44%	40.12%	7.55%

Personalis presently has a consensus price target of $14.25, indicating a potential upside of 1.50%. Sotera Health has a consensus price target of $21.50, indicating a potential upside of 13.82%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Sotera Health beats Personalis on 13 of the 16 factors compared between the two stocks.

How does Personalis compare to Adaptive Biotechnologies?

Personalis (NASDAQ:PSNL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Personalis has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Adaptive Biotechnologies has a net margin of -20.73% compared to Personalis' net margin of -153.84%. Adaptive Biotechnologies' return on equity of -36.81% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

61.9% of Personalis shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 4.2% of Personalis shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adaptive Biotechnologies has higher revenue and earnings than Personalis. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	21.10	-$81.27M	-$1.09	N/A
Adaptive Biotechnologies	$308.08M	12.82	-$59.50M	-$0.41	N/A

Personalis presently has a consensus target price of $14.25, suggesting a potential upside of 1.50%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 1.31%. Given Personalis' higher possible upside, research analysts clearly believe Personalis is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Personalis. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Adaptive Biotechnologies' score of 0.94 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adaptive Biotechnologies beats Personalis on 11 of the 16 factors compared between the two stocks.

How does Personalis compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

61.9% of Personalis shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alamar Biosciences has a net margin of 0.00% compared to Personalis' net margin of -153.84%. Alamar Biosciences' return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Personalis	-153.84%	-46.47%	-35.30%

Alamar Biosciences has higher revenue and earnings than Personalis. Alamar Biosciences is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$100.42M	22.91	-$29.82M	-$1.74	N/A
Personalis	$69.67M	21.10	-$81.27M	-$1.09	N/A

Alamar Biosciences presently has a consensus target price of $31.80, suggesting a potential downside of 4.10%. Personalis has a consensus target price of $14.25, suggesting a potential upside of 1.50%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Alamar Biosciences had 14 more articles in the media than Personalis. MarketBeat recorded 17 mentions for Alamar Biosciences and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Alamar Biosciences' score of 0.57 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alamar Biosciences beats Personalis on 8 of the 14 factors compared between the two stocks.

How does Personalis compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

61.9% of Personalis shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fortrea had 8 more articles in the media than Personalis. MarketBeat recorded 11 mentions for Fortrea and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat Fortrea's score of 0.96 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, Personalis has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Personalis has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.62	-$986.20M	-$0.91	N/A
Personalis	$69.67M	21.10	-$81.27M	-$1.09	N/A

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Personalis	-153.84%	-46.47%	-35.30%

Fortrea currently has a consensus price target of $20.75, suggesting a potential upside of 19.18%. Personalis has a consensus price target of $14.25, suggesting a potential upside of 1.50%. Given Fortrea's stronger consensus rating and higher possible upside, equities analysts plainly believe Fortrea is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Fortrea beats Personalis on 9 of the 16 factors compared between the two stocks.

How does Personalis compare to BioLife Solutions?

Personalis (NASDAQ:PSNL) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

In the previous week, BioLife Solutions had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for BioLife Solutions and 3 mentions for Personalis. Personalis' average media sentiment score of 1.24 beat BioLife Solutions' score of 0.52 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Personalis currently has a consensus price target of $14.25, suggesting a potential upside of 1.50%. BioLife Solutions has a consensus price target of $31.38, suggesting a potential downside of 10.54%. Given Personalis' stronger consensus rating and higher probable upside, analysts plainly believe Personalis is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

BioLife Solutions has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	21.10	-$81.27M	-$1.09	N/A
BioLife Solutions	$96.21M	17.81	-$4.59M	$1.16	30.23

Personalis has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

BioLife Solutions has a net margin of 53.29% compared to Personalis' net margin of -153.84%. BioLife Solutions' return on equity of 2.70% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
BioLife Solutions	53.29%	2.70%	2.49%

Summary

BioLife Solutions beats Personalis on 10 of the 17 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.51B	$9.66B	$7.04B	$13.09B
Dividend Yield	N/A	1.46%	2.57%	10.45%
P/E Ratio	-12.88	60.32	268.81	25.27
Price / Sales	21.10	105.52	562.07	70.86
Price / Cash	N/A	26.25	70.48	50.90
Price / Book	6.24	37.50	12.91	6.24
Net Income	-$81.27M	$56.66B	$3.45B	$347.60M
7 Day Performance	-0.85%	0.30%	1.11%	1.06%
1 Month Performance	-11.08%	1.38%	1.33%	0.81%
1 Year Performance	205.22%	17.34%	62.44%	20.90%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	2.1992 of 5 stars	$14.04 -2.6%	$14.25 +1.5%	+201.3%	$1.51B	$69.67M	N/A	400	Positive News Gap Down
SHC Sotera Health	4.0881 of 5 stars	$18.97 +0.6%	$21.50 +13.3%	+19.9%	$5.38B	$1.16B	33.28	3,000	Analyst Upgrade Insider Trade
ADPT Adaptive Biotechnologies	1.6316 of 5 stars	$25.45 +2.1%	$24.42 -4.1%	+91.5%	$3.98B	$276.98M	N/A	790
ALMR Alamar Biosciences	1.0632 of 5 stars	$27.99 -1.7%	$30.00 +7.2%	N/A	$1.97B	$74.21M	N/A	222	News Coverage Earnings Report Analyst Forecast
FTRE Fortrea	3.9783 of 5 stars	$18.99 +3.0%	$20.75 +9.3%	+120.4%	$1.75B	$2.72B	N/A	14,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. SHC, ADPT, ALMR, FTRE, and BLFS

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Summary

How does Personalis compare to Alamar Biosciences?

Summary

How does Personalis compare to Fortrea?

Summary

How does Personalis compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. SHC, ADPT, ALMR, FTRE, and BLFS

How does Personalis compare to Sotera Health?

Which has better valuation and earnings, PSNL or SHC?

Which has more volatility and risk, PSNL or SHC?

Does the media refer more to PSNL or SHC?

Do insiders and institutionals hold more shares of PSNL or SHC?

Is PSNL or SHC more profitable?

Do analysts rate PSNL or SHC?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Which has more risk & volatility, PSNL or ADPT?

Is PSNL or ADPT more profitable?

Do institutionals & insiders hold more shares of PSNL or ADPT?

Which has preferable earnings and valuation, PSNL or ADPT?

Do analysts recommend PSNL or ADPT?

Does the media favor PSNL or ADPT?

Summary

How does Personalis compare to Alamar Biosciences?

Do institutionals & insiders have more ownership in ALMR or PSNL?

Is ALMR or PSNL more profitable?

Which has higher valuation & earnings, ALMR or PSNL?

Do analysts rate ALMR or PSNL?

Does the media prefer ALMR or PSNL?

Summary

How does Personalis compare to Fortrea?

Do institutionals and insiders have more ownership in FTRE or PSNL?

Does the media prefer FTRE or PSNL?

Which has more volatility and risk, FTRE or PSNL?

Which has preferable earnings and valuation, FTRE or PSNL?

Is FTRE or PSNL more profitable?

Do analysts rate FTRE or PSNL?

Summary

How does Personalis compare to BioLife Solutions?

Does the media favor PSNL or BLFS?

Do institutionals & insiders have more ownership in PSNL or BLFS?

Do analysts rate PSNL or BLFS?

Which has better earnings and valuation, PSNL or BLFS?

Which has more volatility & risk, PSNL or BLFS?

Is PSNL or BLFS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools